Objectives This study aimed to evaluate serum human epididymis protein 4 (HE4) changes
during neoadjuvant chemotherapy (NACT) to establish HE4 predebulking surgery cutoff …

Background Ovarian cancer (OC) is considered the most lethal gynecological cancer, of
which more than 65% cases are diagnosed in advanced stages, requiring platinum-based …

Abstract Human epididymis protein 4 (HE4) is a novel tumour marker in epithelial ovarian
cancer (EOC). Data on its profile and predictive potential for subsequent outcome after …

OBJECTIVE: Optimal surgical outcome has been proved to be one of the most powerful
survival determinants in the management of ovarian cancer patients. Actually, for ovarian …

Background The aim of this study is to evaluate a new tumour marker, HE4, and to compare
it with CA125 in predicting optimal cytoreduction and response to chemotherapy. Thirty …

Epithelial ovarian cancer (EOC) remains the deadliest form of gynecological cancers.
Optimal tumor debulking, no matter the primary or the interval, is the most important …

OBJECTIVES: Epithelial ovarian cancer (EOC) is the major cause of death due to
gynecological malignancies. The most important prognostic factors are residual tumor mass …

Background This study assessed the prognostic value of HE4 marker measurements at
various stages of first-line chemotherapy for ovarian cancer. Methods The study consisted of …

Primary chemotherapy treatment response monitoring in advanced epithelial ovarian cancer
(EOC) is currently based on CT-imaging and serum CA125 values. Serum HE4 profile …

Objectives To assess the prognostic value of human epididymis protein 4 (HE4) kinetics
during and after neoadjuvant chemotherapy (NACT) cycles compared with cancer antigen …